Reviva Pharmaceuticals Holdings Inc — Rendiconto Finanziario (NASDAQ:RVPH) | MetaTrader

Apri il grafico completo

Notizie

Does Cobenfy Have the Potential to Become a Top Drug for BMY?

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.44%

Reviva Pharmaceuticals fissa offerta pubblica da 10 mln $ a 1,50 $

Reviva Pharmaceuticals annuncia offerta pubblica di azioni e warrant

D. Boral Capital declassa il rating di Reviva Pharmaceuticals a Hold

D. Boral Capital downgrades Reviva Pharmaceuticals stock rating to hold

Reviva Pharmaceuticals attua un raggruppamento azionario 1-per-20 il 9 marzo

Reviva Pharmaceuticals to implement 1-for-20 reverse stock split on March 9

Vocal biomarker study supports brilaroxazine’s efficacy in schizophrenia

Chardan Capital avvia copertura su Reviva Pharmaceuticals con rating Buy

Chardan Capital assumes coverage on Reviva Pharmaceuticals stock with Buy rating

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/30/25 - TipRanks.com